Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan

Theodora Hadjistilianou, Gianni Coriolani, Sandra Bracco, Paola Gennari, Mauro Caini, Alfonso Cerase, Daniela Galimberti, Sonia De Francesco, Mariacarla De Luca, Domenico Mastrangelo

Research output: Contribution to journalArticle

Abstract

Purpose: To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible. Methods: Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment. Results: The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case. Conclusions: SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalJournal of Pediatric Ophthalmology and Strabismus
Volume51
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Ophthalmic Artery
Melphalan
Retinoblastoma
Neoplasms
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Pediatrics, Perinatology, and Child Health

Cite this

Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan. / Hadjistilianou, Theodora; Coriolani, Gianni; Bracco, Sandra; Gennari, Paola; Caini, Mauro; Cerase, Alfonso; Galimberti, Daniela; Francesco, Sonia De; Luca, Mariacarla De; Mastrangelo, Domenico.

In: Journal of Pediatric Ophthalmology and Strabismus, Vol. 51, No. 1, 01.2014, p. 32-38.

Research output: Contribution to journalArticle

Hadjistilianou, T, Coriolani, G, Bracco, S, Gennari, P, Caini, M, Cerase, A, Galimberti, D, Francesco, SD, Luca, MD & Mastrangelo, D 2014, 'Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan', Journal of Pediatric Ophthalmology and Strabismus, vol. 51, no. 1, pp. 32-38. https://doi.org/10.3928/01913913-20131203-01
Hadjistilianou, Theodora ; Coriolani, Gianni ; Bracco, Sandra ; Gennari, Paola ; Caini, Mauro ; Cerase, Alfonso ; Galimberti, Daniela ; Francesco, Sonia De ; Luca, Mariacarla De ; Mastrangelo, Domenico. / Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan. In: Journal of Pediatric Ophthalmology and Strabismus. 2014 ; Vol. 51, No. 1. pp. 32-38.
@article{08af4ee06b5845c48c3d6b44e09dea8f,
title = "Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan",
abstract = "Purpose: To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible. Methods: Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment. Results: The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case. Conclusions: SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.",
author = "Theodora Hadjistilianou and Gianni Coriolani and Sandra Bracco and Paola Gennari and Mauro Caini and Alfonso Cerase and Daniela Galimberti and Francesco, {Sonia De} and Luca, {Mariacarla De} and Domenico Mastrangelo",
year = "2014",
month = "1",
doi = "10.3928/01913913-20131203-01",
language = "English",
volume = "51",
pages = "32--38",
journal = "Journal of Pediatric Ophthalmology and Strabismus",
issn = "0191-3913",
publisher = "Slack Incorporated",
number = "1",

}

TY - JOUR

T1 - Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan

AU - Hadjistilianou, Theodora

AU - Coriolani, Gianni

AU - Bracco, Sandra

AU - Gennari, Paola

AU - Caini, Mauro

AU - Cerase, Alfonso

AU - Galimberti, Daniela

AU - Francesco, Sonia De

AU - Luca, Mariacarla De

AU - Mastrangelo, Domenico

PY - 2014/1

Y1 - 2014/1

N2 - Purpose: To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible. Methods: Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment. Results: The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case. Conclusions: SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.

AB - Purpose: To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible. Methods: Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment. Results: The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case. Conclusions: SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84894057773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894057773&partnerID=8YFLogxK

U2 - 10.3928/01913913-20131203-01

DO - 10.3928/01913913-20131203-01

M3 - Article

C2 - 24308859

AN - SCOPUS:84894057773

VL - 51

SP - 32

EP - 38

JO - Journal of Pediatric Ophthalmology and Strabismus

JF - Journal of Pediatric Ophthalmology and Strabismus

SN - 0191-3913

IS - 1

ER -